What's Happening?
Vizgen, a company specializing in spatial biology, has launched a new business unit named Velocity Lab. This unit is designed to generate large-scale spatial data for the development and training of artificial
intelligence (AI) models, catering to both external clients and Vizgen's internal AI initiatives. According to Vizgen president and CEO Rob Carson, there is a growing recognition that novel data types, beyond sheer volume, are crucial for training more effective biological models, and spatial biology data is identified as one such critical type. Velocity Lab will integrate Vizgen's existing fee-for-service operations, providing spatial data services to pharmaceutical companies, academic institutions, and research consortia. The unit offers two primary workflows: the Volumetric Tissue Mapping assay for 3D sample profiling to understand cell neighborhoods and disease microenvironments, and the Merscope CoMap assay, which enables co-detection of protein and RNA targets within the same tissue sample. This initiative aims to produce consistent and reproducible datasets suitable for AI training across various tissues, species, donors, and conditions.
Why It's Important?
The establishment of Velocity Lab by Vizgen signifies a strategic move to capitalize on the increasing demand for AI-driven solutions in drug discovery and development within the U.S. and global biotechnology sectors. By providing high-quality, large-scale spatial biology data, Vizgen positions itself as a key enabler for advancements in precision medicine and therapeutic development. This development is crucial because AI models require vast amounts of reliable data for effective training, and spatial biology offers a unique dimension by revealing the 'where' of biological processes within tissues, which traditional 'bulk' analyses often miss. The ability to consistently generate reproducible datasets at scale addresses a significant bottleneck in AI model development, making these models more robust and clinically relevant. This initiative could accelerate the identification of biomarkers, understanding disease mechanisms, and the development of new treatments, ultimately benefiting patients and driving innovation in the pharmaceutical industry. Furthermore, it creates a new revenue stream for Vizgen and strengthens its competitive position against other life sciences companies like 10x Genomics and Illumina, which are also investing heavily in AI and data-driven biology.
What's Next?
Vizgen plans to expand Velocity Lab's offerings in 2027 to include spatially-resolved functional genomics experiments and whole-transcriptome spatial analysis. The company also aims to significantly scale the unit's capacity to profile hundreds of millions of cells per week. Initial research collaborations are already underway, including a partnership with a large multinational biopharma company for neuroscience drug discovery using Volumetric Tissue Mapping. The Allen Institute is also utilizing Velocity Lab for high-plex multiomics data production to build reference atlases of human tissue. Pricing for Velocity Lab's services will be project-specific, influenced by factors such as the number of genes profiled, panel design, sample numbers, and the inclusion of protein detection. Customers will have options for exclusive datasets or collaborative agreements where data can contribute to Vizgen's broader AI model development efforts. As the unit matures, it is expected to become a significant contributor to Vizgen's revenue, indicating a strong commitment to the long-term integration of AI and spatial biology.
Beyond the Headlines
The launch of Velocity Lab highlights a broader trend in the life sciences: the convergence of advanced biological imaging, genomics, and artificial intelligence. This integration is not merely about technological advancement but represents a paradigm shift in how biological research is conducted and how diseases are understood and treated. The emphasis on 'spatial' data underscores the critical importance of cellular context and tissue architecture, moving beyond reductionist approaches to a more holistic view of biological systems. This shift has profound implications for ethical considerations, particularly regarding data privacy and the responsible use of AI in healthcare. The need for standardized data formats and robust computational workflows, as discussed by Dr. Jasmine Plummer, remains a significant challenge that initiatives like Velocity Lab aim to address. The long-term success of such ventures will depend on their ability to not only generate data but also to develop interpretable AI models that can translate complex spatial information into actionable clinical insights, ultimately transforming precision medicine and drug development.
